Concord Biotech (BOM:543960) Operating Margin %: 30.36% (As of Mar. 2026) — 19% Below Median


BOM:543960 Concord Biotech Ltd BOM:543960
68 GF Score
Price ₹1,277.85
GF Value ₹1,640.84
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Concord Biotech Operating Margin %?

Concord Biotech BOM:543960 +1.24% 68 Operating Margin % is 30.36% as of Mar. 2026, which is 19% below its 10-year median of 37.66. GuruFocus rates BOM:543960 with a GF Score™ of 68/100 and a GF Value™ of ₹1,640.84 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 941 Biotechnology companies, Concord Biotech ranks better than 92.35% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Concord Biotech's Operating Income for the three months ended in Mar. 2026 was ₹990 Mil. Concord Biotech's Revenue for the three months ended in Mar. 2026 was ₹3,261 Mil. Therefore, Concord Biotech's Operating Margin % for the quarter that ended in Mar. 2026 was 30.36%.

Warning Sign:

Concord Biotech Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -7%.

The historical rank and industry rank for Concord Biotech's Operating Margin % or its related term are showing as below:

BOM:543960' s Operating Margin % Range Over the Past 10 Years
Min: 27.77   Med: 37.66   Max: 50.2
Current: 27.77


BOM:543960's Operating Margin % is ranked better than
92.35% of 941 companies
in the Biotechnology industry
Industry Median: -86.89 vs BOM:543960: 27.77

Concord Biotech's 5-Year Average Operating Margin % Growth Rate was -7.00% per year.

Concord Biotech's Operating Income for the three months ended in Mar. 2026 was ₹990 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹2,929 Mil.


Concord Biotech  (BOM:543960) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Concord Biotech Operating Margin % Related Terms


Concord Biotech Operating Margin % Historical Data

* Premium members only.

The historical data trend for Concord Biotech's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Biotech Operating Margin % Chart

Concord Biotech Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Margin %
Get a 7-Day Free Trial 33.33 36.69 38.70 37.66 27.77

Concord Biotech Quarterly Data
Mar20 Mar21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.90 21.38 28.37 28.89 30.36

BOM:543960 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Concord Biotech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Biotech Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concord Biotech's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Concord Biotech's Operating Margin % falls into.


BOM:543960
68GF Score
Concord Biotech Ltd BOM:543960
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Biotech Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Concord Biotech's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (A: Mar. 2026 ) / Revenue (A: Mar. 2026 )
=2929.413 / 10548.907
=27.77 %

Concord Biotech's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=989.876 / 3260.796
=30.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 30.36% mean?
Concord Biotech (BOM:543960) has a Operating Margin % of 30.36% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Concord Biotech and its competitors. This is 19% below median its historical median of 37.66. Over the past decade, Concord Biotech's Operating Margin % has ranged from 27.77 to 50.20. According to the industry distribution chart, Concord Biotech ranks #72 out of 941 companies in the Biotechnology industry, placing it in the top 7.7%.
Is Concord Biotech's Operating Margin % too high?
Concord Biotech's current Operating Margin % of 30.36% is 19% below median its 10-year median of 37.66. Over the past 10 years, this metric has ranged from a low of 27.77 to a high of 50.20. Based on the distribution chart, Concord Biotech ranks #72 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Concord Biotech has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #72 out of 941 companies for Operating Margin %. This places Concord Biotech in the top 8% of its industry — outperforming the majority of peers. Historically, Concord Biotech's own Operating Margin % has ranged from 27.77 to 50.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Concord Biotech and its competitors. Concord Biotech's current Operating Margin % is 30.36%, which is 19% below median its own 10-year median of 37.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (BOM:543960) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,640.84, compared to a current price of ₹1,277.85 — trading 22.1% below its estimated fair value. The current Operating Margin % is 30.36%, which is 19% below median its 10-year median of 37.66. Concord Biotech's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Concord Biotech (BOM:543960), the current Operating Margin % is 30.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Biotech (BOM:543960) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued. The current stock price of ₹1,277.85 is trading 22.1% below its estimated GF Value™ of ₹1,640.84. GuruFocus considers Concord Biotech to be Modestly Undervalued.

Key valuation signals for BOM:543960:

  • Operating Margin %: 30.36% (19% below median its 10-year median of 37.66)
  • GF Value™: ₹1,640.84 vs. price of ₹1,277.85 (22.1% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Concord Biotech Business Description

Other Exchanges CONCORDBIO:India
Address Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score

Get the complete analysis for BOM:543960

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,277.85
Price
₹1,640.84
GF Value